Process For Generating Nanometer Sized Particles That Increase Oxygen Levels In Mammalian Tissues

Abstract

A composition and process to produce poly-oxygenated metal hydroxide particles on the nanometer size scale. The relevant particle size includes all size populations ranging from 1 nanometer (nm) to 3000 nanometers (nm) or 3 micrometer (μm) in particle diameter. Filtering may be used to create homogeneous particle sizes. Exemplary delivery applications include inhalation, ingestion, anally, vaginally, dermal penetration or permeation, intramuscular injection, and intravenous injection to treat numerous conditions and diseases of mammals, including humans and animals.

1 . A process for generating reduced sized particles of poly-oxygenated metal hydroxide, comprising the step of:
 obtaining predetermined quantity of poly-oxygenated metal hydroxide material;   determining process variables as a function of the predetermined quantity; and   processing the predetermined quantity of poly-oxygenated metal hydroxide material using the determined process variables to create a processed quantity poly-oxygenated metal hydroxide material having particle sizes of less than or equal to 3 μm in diameter.   
     
     
         2 . The process as specified in  claim 1  wherein the processed quantity of oxygenated metal hydroxide material is homogenous. 
     
     
         3 . The process as specified in  claim 1 , further comprising the step of:
 analyzing the processed quantity of poly-oxygenated metal hydroxide material to confirm the particle sizes are less than or equal to 3 μm in diameter.   
     
     
         4 . The process as specified in  claim 1  further comprising the step of using a planetary motion machine to perform the processing step. 
     
     
         5 . The process as specified in  claim 1  wherein the process variables are determined based on a milling scale. 
     
     
         6 . The process as specified in  claim 1  wherein the poly-oxygenated metal hydroxide material comprises a poly-oxygenated aluminum hydroxide. 
     
     
         7 . The process as specified in  claim 2  wherein the processing step creates a homogenous quantity of poly-oxygenated metal hydroxide material having particle sizes of less than or equal to 250 nm diameter. 
     
     
         8 . A composition, comprising:
 a quantity poly-oxygenated aluminum hydroxide having particle sizes of less than or equal to 3 μm in diameter, wherein the poly-oxygenated metal hydroxide comprises a clathrate containing free oxygen gas (O 2 ) molecules.   
     
     
         9 . The composition as specified in  claim 8 , wherein the quantity of poly-oxygenated aluminum hydroxide is homogeneous. 
     
     
         10 . The composition as specified in  claim 8 , wherein the homogenous quantity of poly-oxygenated aluminum hydroxide has particle sizes of less than or equal to 250 nm in diameter. 
     
     
         11 . canceled 
     
     
         12 . canceled 
     
     
         13 . The composition as specified in  claim 8  wherein poly-oxygenated aluminum hydroxide is therapeutically effective in treating a condition of a mammal. 
     
     
         14 . The composition as specified in  claim 8  wherein the poly-oxygenated aluminum hydroxide is configured to be intravenously delivered to a mammal. 
     
     
         15 . The composition as specified in  claim 8  wherein the poly-oxygenated aluminum hydroxide is configured to not create an immune response of the mammal. 
     
     
         16 . The composition as specified  claim 8  wherein the poly-oxygenated aluminum hydroxide is configured to deposit deep into a lung and perfuse the oxygen gas out to lining of the lung. 
     
     
         17 . The composition as specified in  claim 8  wherein the oxygen gas is configured to penetrate through epidermis and dermis layers of skin and reside in a subcutaneous layer of the skin. 
     
     
         18 . The composition as specified in  claim 8  wherein the oxygen gas is configured to absorb through lining of an esophagus and a stomach. 
     
     
         19 . The composition as specified in  claim 8  wherein the poly-oxygenated hydroxide is configured to traverse a blood brain barrier (BBB) of a mammal. 
     
     
         20 . The composition as specified in  claim 8  wherein the poly-oxygenated aluminum hydroxide is configured to stay in a capillary, vein, or artery linings of a mammal circulatory system and not passively diffuse past a lining into surrounding tissue.